Lebrikizumab: all 46 studies that test it

Page 1 of 1. Open to participants first (6), then studies with results posted, then the rest; newest registration first within each.

• A Study of Lebrikizumab in Adults and Adolescents With Face and Neck Atopic DermatitisNot yet recruitingNCT07873801Phase 3
• AD Treatment Optimization With Ebglyss in Real-World Practice: A Multicenter Study of Patient-Centered OutcomesNot yet recruitingNCT07856134Phase 4
• Efficacy and Speed of Response of Lebrikizumab in High-Burden Prurigo Nodularis PatientsNot yet recruitingNCT07620561Phase 2
• A Study of Lebrikizumab in Adults With Nummular EczemaRecruitingNCT07542483Phase 3
• Utilization of a Microdevice for Psoriasis and Atopic DermatitisNot yet recruitingNCT07352566Phase 4
• A Study to Assess the Long-Term Safety and Efficacy of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic DermatitisEnrolling by invitationNCT05735483Phase 3
• A Study of Lebrikizumab (LY3650150) With/Without Topical Corticosteroid Treatment in Participants With Moderate-to-Severe Atopic DermatitisCompletedNCT06280716Phase 3Results posted
• A Study to Investigate the Safety and Pharmacokinetics of Lebrikizumab in Healthy Chinese ParticipantsCompletedNCT06243198Phase 1Results posted
• Effectiveness and Safety of Lebrikizumab Treatment in Adults and Adolescents With Moderate-to-Severe Atopic DermatitisCompletedNCT05990725Phase 3Results posted
• A Study of (LY3650150) Lebrikizumab to Assess the Safety and Efficacy of Adult and Adolescent Participants With Moderate-to-Severe Atopic Dermatitis and Skin of ColorCompletedNCT05372419Phase 3Results posted
• A Study of Lebrikizumab (LY3650150) in Adult and Adolescent Participants With Moderate-to-Severe Atopic Dermatitis Previously Treated With DupilumabCompletedNCT05369403Phase 3Results posted
• A Study of Lebrikizumab in Combination With Topical Corticosteroids in Patients With Atopic Dermatitis (AD) That Are Not Adequately Controlled With or Are Non-eligible for CyclosporineCompletedNCT05149313Phase 3Results posted
• A Study of Lebrikizumab (LY3650150) Administered by Two Different Devices in Healthy ParticipantsCompletedNCT04840901Phase 1Results posted
• A Study of Lebrikizumab (LY3650150) in Combination With Topical Corticosteroids in Japanese Participants With Moderate-to-Severe Atopic DermatitisCompletedNCT04760314Phase 3Results posted
• A Study of Lebrikizumab (LY3650150) on Vaccine Response in Adults With Atopic Dermatitis (ADopt-VA)CompletedNCT04626297Phase 3Results posted
• Long-term Safety and Efficacy Study of Lebrikizumab (LY3650150) in Participants With Moderate-to-Severe Atopic Dermatitis (ADjoin)CompletedNCT04392154Phase 3Results posted
• Study to Assess the Safety and Efficacy of Lebrikizumab (LY3650150) in Adolescent Participants With Moderate-to-Severe Atopic DermatitisCompletedNCT04250350Phase 3Results posted
• Safety and Efficacy of Lebrikizumab (LY3650150) in Combination With Topical Corticosteroid in Moderate-to-Severe Atopic Dermatitis.CompletedNCT04250337Phase 3Results posted
• Evaluation of the Efficacy and Safety of Lebrikizumab (LY3650150) in Moderate to Severe Atopic DermatitisCompletedNCT04178967Phase 3Results posted
• Evaluation of the Efficacy and Safety of Lebrikizumab (LY3650150) in Moderate to Severe Atopic Dermatitis (ADvocate1)CompletedNCT04146363Phase 3Results posted
• A Study of Lebrikizumab (LY3650150) in Participants With Moderate-to-Severe Atopic DermatitisCompletedNCT03443024Phase 2Results posted
• A Study to Evaluate Safety and Efficacy of Lebrikizumab in Participants With Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT02546700Phase 2Results posted
• A Study Evaluating the Efficacy and Safety of Lebrikizumab in Adult Patients With Mild to Moderate AsthmaCompletedNCT02104674Phase 3Results posted
• A Study of Lebrikizumab in Adolescent Participants With Uncontrolled Asthma Who Are on Inhaled Corticosteroids and a Second Controller MedicationTerminatedNCT01875003Phase 3Results posted
• A Study of Lebrikizumab in Participants With Idiopathic Pulmonary Fibrosis (IPF)CompletedNCT01872689Phase 2Results posted
• A Study of Lebrikizumab in Participants With Uncontrolled Asthma Who Are on Inhaled Corticosteroids and a Second Controller MedicationCompletedNCT01867125Phase 3Results posted
• A Study to See How Well Lebrikizumab Works in Adults and Adolescents With Moderate Atopic Dermatitis (Eczema) and High Itch BurdenCompletedNCT07006792Phase 4
• A Study to Investigate the Efficacy and Safety of Lebrikizumab in Participants With Moderate-to-Severe Atopic Hand and Foot DermatitisCompletedNCT06921759Phase 3
• Lebrikizumab in Moderate-to-severe Atopic DermatitisActive, not recruitingNCT06906497Phase 4
• A Study of Lebrikizumab Treatment in Adults and Adolescents With Moderate-to-Severe Atopic DermatitisActive, not recruitingNCT06526182Phase 3
• Long-term Safety and Efficacy of Lebrikizumab in Adult and Adolescent Participant With Moderate-to-Severe Atopic DermatitisCompletedNCT05916365Phase 3
• A Study of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic DermatitisActive, not recruitingNCT05559359Phase 3
• A Single-Arm Study to Evaluate Administration of Lebrikizumab by Participants or Caregivers in the Home SettingWithdrawnNCT02546869Phase 3
• A Bioequivalence Study of Subcutaneous (SC) Lebrikizumab Administered by Needle and Syringe or by Prefilled Syringe With Needle Safety Device (PFS-NSD)CompletedNCT02486809Phase 1
• A Study to Evaluate the Safety of Lebrikizumab Compared to Topical Corticosteroids in Adult Patients With Atopic DermatitisCompletedNCT02465606Phase 2
• A Study of Lebrikizumab in Participants With Persistent Moderate to Severe Atopic DermatitisCompletedNCT02340234Phase 2
• A Study Evaluating the Effects of Lebrikizumab on Airway Eosinophilic Inflammation in Participants With Uncontrolled AsthmaCompletedNCT02099656Phase 2
• A Study of Lebrikizumab (RO5490255) in Participants With Severe Oral Corticosteroids (OCS) Dependent AsthmaCompletedNCT01987492Phase 2
• A Study of Lebrikizumab in Participants With Uncontrolled Asthma on Inhaled Corticosteroids and a Second Controller MedicationCompletedNCT01868061Phase 3
• A Study of Lebrikizumab in Patients With Uncontrolled Asthma Who Are on Inhaled Corticosteroids and A Second Controller Medication (VERSE)CompletedNCT01545453Phase 2
• A Study of Lebrikizumab in Patients Whose Asthma is Uncontrolled With Inhaled Corticosteroids and A Second Controller Medication (LUTE)CompletedNCT01545440Phase 2
• A Study of Lebrikizumab in Healthy Japanese and Caucasian VolunteersCompletedNCT01423318Phase 1
• A Study to Evaluate Lebrikizumab (MILR1444A) in Adult Patients With Asthma Who Are Not Taking Inhaled CorticosteroidsCompletedNCT00971035Phase 2
• A Study of Lebrikizumab (MILR1444A) in Adult Patients With Asthma Who Are Inadequately Controlled on Inhaled CorticosteroidsCompletedNCT00930163Phase 2
• A Study to Evaluate MILR1444A in the Prevention of Allergen-Induced Airway Obstruction in Adults With Mild Allergic AsthmaCompletedNCT00781443Phase 2
• Safety and Efficacy Study of TNX-650 to Treat Refractory Hodgkin's LymphomaStatus unknownNCT00441818Phase 1/2

← Lebrikizumab overview